Fennec Pharmaceuticals Inc. (FENC) analyst actions
Rating and price-target actions on FENC in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the FENC overview →
2 measured FENC analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 | Press release | +0.00% | +0.37% | |
| Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss | Press release | -1.80% | -2.06% |
Keep exploring
More FENC: earnings → · SEC filings → · FENC overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SOPHIRIS BIO INC (SPHS) | 366 | -0.23% | 37% |
| EISAI CO S/ADR (ESALY) | 365 | 0.00% | 33% |
| RadNet, Inc. (RDNT) | 364 | +0.09% | 53% |
| Aerpio Pharmaceuticals, Inc (ARPO) | 363 | 0.00% | 32% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.